Founded in 2004, the company is based in San Diego, California and focuses on addressing unmet needs in cancer treatment. Proacta's foundation includes intellectual property developed at the University of Auckland in New Zealand and Stanford University in the United States, with a patent family covering a range of hypoxia-activated prodrugs aimed at cancer treatment.
Their lead compound, PR610, is derived from a pipeline of hypoxia-activated tyrosine-kinase inhibitor prodrugs designed to release active tyrosine-kinase inhibitors selectively within the hypoxic environment common to many solid tumors. The company aims to enhance efficacy and reduce toxicity compared to existing therapies.
Proacta has successfully raised $43 million through two private financings, with investors including Alta Partners, Clarus Ventures, Delphi Ventures, Endeavour Capital (New Zealand), GBS Venture Partners (Australia), Genentech, No 8 Ventures (New Zealand), and Roche. Their last investment was a $500.00K debt financing in December 2011.
Proacta's focus on targeted cancer therapy and its strong investor backing position it as a promising player in the biotechnology and healthcare industries.
